Member Info for KaChing

Rame Energy PLC ‏@RameEnergy 33s33 seconds ago "Latin America's Hottest Renewables Market Gets Government Boost" #Renewables #Chile #Rame http://bit.ly/1LgpYsQ

Hopefully the rest of the market will start seeing what we think we see now, only they will be paying higher prices .... hopefully, lol

It’s worthless looking at the fundies here at the moment, this is all about whether the SP will gain some momentum either before or on a bit of positive news once the placing overhang has petered out. There are some that call it “market mechanics” and while I don’t call it investing it does work occasionally, so for me this share is much more of a punt and not one I could post any fundamental positives on because that really would be pure ramping, lol They would have raised somewhere under £2.5m after fees, not the £3m they were hoping for if all the open offer shares were taken up, but it should hopefully underpin the company for a while and also give the SP a “bottom” ish.

Interesting little play, fundies look terrible, but fundies look terrible on most AIM shares, lol, they’ve raised £10.6m since 2013 (I haven’t gone back any further), second half revenue is as they say lower than the first half. Obviously they have recently won a few contracts using their new business model (anyone got any figures for the new lease agreements?) in fairly quick succession which points to it at least being of interest to potential customers. I’d be gobsmacked if they got anywhere near £6m for IntelliSAW as any potential buyer would be aware of their situation and would want to drive a hard bargain, but anything they can get will obviously help funding going forward as well as cut a few costs. The above is kinda negative but going forward with the right news from these levels then it does look like there is potential ……. I’ll keep an eye on what you techies are saying

Yeah, it’s very important and hopefully the increasing revenues which in turn should see VENN become profitable this year will also feed down to positive cash flow …… day to day cash flow is also helped by upfront payments and then stage payments as the trials progress. They seem to have a good pipeline of potential new contracts which as of July was still an impressive €18m and that’s after converting €9m into actual contracts (it’s relevant because at the end of last year the pipeline was €18m which means new pipeline opportunities as well as conversion are looking very strong) They’ve invested for growth and they are now seeing it …..

“Some of the smaller hybrid contract research firms are trading at 2.5 times and above – which makes a mockery of Venn’s current stock market rating of one times forward revenues. “We have a business doubling year on year, with good fee income that is expected to be profitable this year. You have some technology upside in there, but this is a real company making real money,” said Richardson. http://www.proactiveinvestors.co.uk/companies/news/108395/venn-life-sciences-is-proof-that-the-market-doesn-t-always-get-it-right-108395.html Somebody stop me

"Time to get in" ....... does that sound a bit rampy? apologies if it does, lol

Before the CEO starts pumping it ...... he didn't actually say pumping, but near enough, lol

Just a reminder, from the CEO's mouth ....... Profitable this year ....... oo-er

Everyone like a video http://www.proactiveinvestors.co.uk/companies/stocktube/3909/venn-life-sciences-riding-the-biotech-wave-3909.html

Venn Life Sciences (LON:VENN) said its revenues in the first half are 170% up on the year earlier as it gave an upbeat assessment of prospects. The growing clinical research group said billings exceeded €4mln in the six months to June 30 driven by contract wins totalling €9mln in the period. Chief executive Tony Richardson said: "Our fee income figures highlight the steady and consistent growth of the company year on year with both repeat business and organic growth contributing to our excellent results and ability to win projects internationally. “Our market continues to grow steadily and with a healthy pipeline of prospects we are well positioned to deliver further growth." Venn’s bedrock business, as mentioned earlier, is contract research. It has 110 staff on its books and offices in five European countries. At this size it isn’t going to go toe to toe with the sector’s big boys. But it is, as its release Thursday reveals, winning some significant new business. Its recent focus has been phase II clinical trials and post-approval studies. If the company’s outsourcing business provides the bedrock to the investment proposition, Venn’s Innovenn arm represents the blue sky. Mixed metaphors aside, the business is primed and entering the commercial phase. Its most advanced product, Labskin, is a 3D living skin equivalent that is a unique alternative to animal testing for dermatological purposes and has the ability to allow microorganisms to grow on its surface. It is has won its first customer, an unnamed major pharma company, and is gearing up to sell the product. However, it also has the capacity to bring testing in-house, which will complement what it already does in the CRO side of the business. It is early days, but there are multiple applications for this innovative product. Innovenn is also developing an anti-acne treatment that is “around six months away from being a licensable technology”. http://www.proactiveinvestors.co.uk/companies/news/109924/venn-life-sciences-trading-strongly-109924.html

24p that would be nice

At the moment the revenue that is booked they class as fees, they then account for Direct Project and Administrative Costs to leave either an Operating profit or loss …… in other words they don’t show what we would normally class as a gross margin. From looking at previous results I’d say there is a good chance that the first half is at least close to breakeven if not better ……. IMO and the usual. Winning an average of just over €1.2m in contracts per month over the last 14 months is an impressive achievement and shows that the business model looks good. At the end of last year they said they had contracted revenue for 2016 in excess of €6m …… it’s going to be better than that now! They also said “the Company is confident that it will deliver profitability and significant revenue growth next year.” ……. I’d say that it’s a good bet they will deliver off the back of €17m in contracts

It won’t be long before the market starts to factor in the potential here, mind you I said/thought that in Jan, lol The contracts that VENN win are generally several years in length which gives them clarity over projected revenue etc. …… they are also structured so that when a stage is met an invoice is sent and cash is received meaning cash flow should be ok. €17m worth of contracts in the last 14 months, surely that has to grab some attention!

Over €17m in contracts won in the last 14 months In the last 8 months of 2014 they won €8m worth of contracts, in the first six months of this year they have won over €9m worth of contracts …… Now that’s what you call good progress!

That RNS just underlines the progress being made and the nature of the contracts bodes very well for revenue growth going forward as well as cash generation and hopefully a first profit in the not too distant future.

BloombergNEF ‏@BloombergNEF 4m4 minutes ago Chilean mines turn to renewables and save $20 per megawatt hour via @WSJ @DubeRyan http://on.wsj.com/1EmpLfK

Cash Generator https://www.youtube.com/watch?v=G2IUYgIDenU&feature=youtu.be

Cheers Fred for taking the time to get clarification.

and ....... "We see a big opportunity for our unique polymer technologies in Byotrol's anti-microbial systems. We look forward to taking our jointly-developed products to our customers worldwide." said Thierry Sclapari, Global Vice President, Home and Personal Care, Solvay Novecare